Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.

Brandsma AM, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen JHM, Rösner T, Valerius T, Leusen JHW, Ten Broeke T.

Front Immunol. 2019 Apr 11;10:704. doi: 10.3389/fimmu.2019.00704. eCollection 2019.

2.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.

PMID:
30824613
3.

FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.

Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK.

Front Immunol. 2019 Jan 30;9:3124. doi: 10.3389/fimmu.2018.03124. eCollection 2018.

4.

CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.

Valerius T, Rösner T, Leusen JHW.

N Engl J Med. 2019 Jan 31;380(5):496-7. doi: 10.1056/NEJMc1816156. No abstract available.

PMID:
30702240
5.

Myeloid immune-checkpoint inhibition enters the clinical stage.

van den Berg TK, Valerius T.

Nat Rev Clin Oncol. 2019 May;16(5):275-276. doi: 10.1038/s41571-018-0155-3. No abstract available.

PMID:
30573788
6.

Immune Effector Functions of Human IgG2 Antibodies against EGFR.

Rösner T, Kahle S, Montenegro F, Matlung HL, Jansen JHM, Evers M, Beurskens F, Leusen JHW, van den Berg TK, Valerius T.

Mol Cancer Ther. 2019 Jan;18(1):75-88. doi: 10.1158/1535-7163.MCT-18-0341. Epub 2018 Oct 3.

PMID:
30282813
7.

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

Engelberts PJ, Breij ECW, Valerius T, Schuurman J, Parren PWHI, Beurskens FJ.

J Immunol. 2018 Apr 15;200(8):2517. doi: 10.4049/jimmunol.1800233. No abstract available.

8.

New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.

Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW.

Br J Haematol. 2018 Mar;180(6):808-820. doi: 10.1111/bjh.15132. Epub 2018 Feb 22.

PMID:
29468712
9.

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.

Klausz K, Cieker M, Kellner C, Oberg HH, Kabelitz D, Valerius T, Burger R, Gramatzki M, Peipp M.

Oncotarget. 2017 Sep 5;8(44):77552-77566. doi: 10.18632/oncotarget.20641. eCollection 2017 Sep 29.

10.

Antibody Isotypes for Tumor Immunotherapy.

Kretschmer A, Schwanbeck R, Valerius T, Rösner T.

Transfus Med Hemother. 2017 Sep;44(5):320-326. doi: 10.1159/000479240. Epub 2017 Sep 7. Review.

11.

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.

Wirt T, Rosskopf S, Rösner T, Eichholz KM, Kahrs A, Lutz S, Kretschmer A, Valerius T, Klausz K, Otte A, Gramatzki M, Peipp M, Kellner C.

Transfus Med Hemother. 2017 Sep;44(5):292-300. doi: 10.1159/000479978. Epub 2017 Sep 11.

12.

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.

Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C.

Blood. 2017 Sep 28;130(13):1543-1552. doi: 10.1182/blood-2017-01-764316. Epub 2017 Jul 11.

13.

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. No abstract available.

PMID:
28449349
14.

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PW, Valerius T.

J Immunol. 2017 Feb 15;198(4):1585-1594. doi: 10.4049/jimmunol.1601268. Epub 2017 Jan 6.

15.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.

J Immunol. 2016 Dec 15;197(12):4829-4837. Epub 2016 Nov 2.

16.

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.

Oncoimmunology. 2015 Jun 5;5(1):e1058459. eCollection 2016.

17.

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T.

Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3.

18.

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.

Derer S, Cossham M, Rösner T, Kellner C, Beurskens FJ, Schwanbeck R, Lohse S, Sina C, Peipp M, Valerius T.

J Immunol. 2015 Nov 15;195(10):5077-87. doi: 10.4049/jimmunol.1501458. Epub 2015 Oct 16.

19.

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.

Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, Boross P, Rouwendal G, Leusen JH.

MAbs. 2016;8(1):87-98. doi: 10.1080/19420862.2015.1106658. Epub 2015 Oct 14. Erratum in: MAbs. 2017 Jan;9(1):165.

20.

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.

Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.

Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25.

21.

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.

Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, Gramatzki M, Kellner C.

Oncotarget. 2015 Oct 13;6(31):32075-88. doi: 10.18632/oncotarget.5135.

22.

The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.

Klausz K, Kellner C, Derer S, Valerius T, Staudinger M, Burger R, Gramatzki M, Peipp M.

J Immunol Methods. 2015 Mar;418:75-83. doi: 10.1016/j.jim.2015.02.002. Epub 2015 Feb 18.

PMID:
25701195
23.

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

Rösner T, Lohse S, Peipp M, Valerius T, Derer S.

J Immunol. 2014 Aug 1;193(3):1485-95. doi: 10.4049/jimmunol.1400329. Epub 2014 Jun 27.

24.

Complement in antibody-based tumor therapy.

Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T.

Crit Rev Immunol. 2014;34(3):199-214. Review.

PMID:
24941073
25.

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization.

Derer S, Kellner C, Rösner T, Klausz K, Glorius P, Valerius T, Peipp M.

Methods Mol Biol. 2014;1131:525-40. doi: 10.1007/978-1-62703-992-5_33.

PMID:
24515488
26.

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.

Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, Leusen JH, Valerius T.

MAbs. 2013 Nov-Dec;5(6):936-45. doi: 10.4161/mabs.26396.

27.

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.

Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M.

MAbs. 2014 Mar-Apr;6(2):409-21. doi: 10.4161/mabs.27457. Epub 2013 Dec 11.

28.

Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.

Koch T, Derer S, Staudinger M, Rossen K, Glorius P, Peipp M, Kellner C, Kunzendorf U, Valerius T, Dechant M.

Am J Nephrol. 2013;38(5):379-87. doi: 10.1159/000355972. Epub 2013 Oct 23.

PMID:
24157422
29.

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.

EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929.

30.

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.

Kellner C, Derer S, Valerius T, Peipp M.

Methods. 2014 Jan 1;65(1):105-13. doi: 10.1016/j.ymeth.2013.06.036. Epub 2013 Jul 9.

PMID:
23851282
31.

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies.

Derer S, Lohse S, Valerius T.

Oncoimmunology. 2013 May 1;2(5):e24052.

32.

An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.

Rösner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, Peipp M, Valerius T.

Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7. No abstract available.

PMID:
23294176
33.

Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies.

Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, Peipp M, Valerius T.

J Immunol. 2012 Dec 1;189(11):5230-9. doi: 10.4049/jimmunol.1202037. Epub 2012 Oct 24.

34.

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M.

J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.

35.

Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.

Derer S, Kellner C, Berger S, Valerius T, Peipp M.

Methods Mol Biol. 2012;907:519-36. doi: 10.1007/978-1-61779-974-7_30.

PMID:
22907372
36.

Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, Valerius T.

J Biol Chem. 2012 Jul 20;287(30):25139-50. doi: 10.1074/jbc.M112.353060. Epub 2012 Jun 7.

37.

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M.

Leukemia. 2013 Jan;27(1):190-201. doi: 10.1038/leu.2012.150. Epub 2012 Jun 4.

PMID:
22660187
38.

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T.

Neoplasia. 2012 Mar;14(3):190-205.

39.

Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548. doi: 10.1073/pnas.1203736109. Epub 2012 Mar 19. No abstract available.

40.

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, Repp R, Humpe A, Gramatzki M, Peipp M.

Leukemia. 2012 Apr;26(4):830-4. doi: 10.1038/leu.2011.288. Epub 2011 Oct 18. No abstract available.

PMID:
22005785
41.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
42.

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.

Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S, Glorius P, Muskulus A, de Goeij BE, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Aug 31;371(1-2):122-33. doi: 10.1016/j.jim.2011.06.023. Epub 2011 Jun 30.

PMID:
21756911
43.

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T.

Cancer Sci. 2011 Oct;102(10):1761-8. doi: 10.1111/j.1349-7006.2011.02019.x. Epub 2011 Aug 4.

44.

Molecular engineering to improve antibodies' anti-lymphoma activity.

Peipp M, van de Winkel JG, Valerius T.

Best Pract Res Clin Haematol. 2011 Jun;24(2):217-29. doi: 10.1016/j.beha.2011.03.004. Epub 2011 May 7. Review.

PMID:
21658620
45.

Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.

Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, Lohse S, Glennie MJ, Medema JP, van Egmond M.

J Immunol. 2011 Jul 15;187(2):726-32. doi: 10.4049/jimmunol.1002581. Epub 2011 Jun 8.

46.

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.

Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T.

J Immunol. 2011 Mar 15;186(6):3770-8. doi: 10.4049/jimmunol.1003082. Epub 2011 Feb 11.

47.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW.

J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.

48.

Fcgamma receptor polymorphisms as biomarkers for epidermal growth factor receptor antibodies.

Valerius T.

J Clin Oncol. 2010 Aug 10;28(23):e393; author reply e394-6. doi: 10.1200/JCO.2010.28.7342. Epub 2010 Jun 14. No abstract available.

PMID:
20547983
49.

Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.

Lohse S, Peipp M, Beyer T, Valerius T, Dechant M.

Arch Immunol Ther Exp (Warsz). 2010 Aug;58(4):303-12. doi: 10.1007/s00005-010-0081-2. Epub 2010 May 28.

PMID:
20508996
50.

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.

Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, Lazar GA, Schneider-Merck T, Peipp M, Valerius T.

Cancer Sci. 2010 May;101(5):1080-8. doi: 10.1111/j.1349-7006.2010.01505.x. Epub 2010 Jan 20.

Supplemental Content

Loading ...
Support Center